Roche eyes alternate mode of administration for Ocrevus in MS

Roche’s Phase III trial for Ocrevus (ocrelizumab) as a subcutaneous injection met its primary and secondary endpoints in patients with primary progressive and relapsing forms of multiple sclerosis (MS).